Advertisement
Advertisement
AKBA
Akebia Therapeutics, Inc.
1.16
USDSponsored
-0.02
-1.69%
May 08, 15:58 UTC -4
Closed
Pre-Market
1.17
+0.01
+0.52%
AKBA Earnings Reports
Positive Surprise Ratio
AKBA beat 18 of 42 last estimates.
43%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$53.54M
/-$0.03
Implied change from Q1 26 (Revenue/ EPS)
+0.01%
/--
Implied change from Q2 25 (Revenue/ EPS)
-14.29%
/--
Akebia Therapeutics, Inc. earnings per share and revenue
On May 07, 2026, AKBA reported earnings of -0.03 USD per share (EPS) for Q1 26, missing the estimate of -0.02 USD, resulting in a -4.90% surprise. Revenue reached 53.54 million, compared to an expected 52.70 million, with a 1.59% difference. The market reacted with a -20.27% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 53.54 million USD, implying an increase of 0.00% EPS, and increase of 0.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
Quoin Pharmaceuticals, Ltd. - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.96
Actual
-$1.77
Surprise
+9.93%
FAQ
What were Akebia Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Akebia Therapeutics, Inc. reported EPS of -$0.03, missing estimates by -4.9%, and revenue of $53.54M, 1.59% above expectations.
How did the market react to Akebia Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved down -20.27%, changed from $1.48 before the earnings release to $1.18 the day after.
When is Akebia Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Akebia Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Akebia Therapeutics, Inc. is expected to report EPS of -$0.03 and revenue of $53.54M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement